Amoy Diagnostics Co Ltd Market Cap ($1.09 Billion)
Market Cap & Net Worth: Amoy Diagnostics Co Ltd (300685)
Amoy Diagnostics Co Ltd market cap. Amoy Diagnostics Co Ltd (SHE:300685) has a market capitalization of $1.09 Billion (CN¥7.45 Billion) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #8199 globally and #1805 in its home market, demonstrating a 5.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amoy Diagnostics Co Ltd's stock price CN¥19.09 by its total outstanding shares 390105169 (390.11 Million). Also see 300685 cash generation efficiency for how efficiently the company converts equity into cash flow.
Amoy Diagnostics Co Ltd Market Cap History (2017–2026)
Amoy Diagnostics Co Ltd market cap history from 2017 to 2026. Data shows growth from $1.03 Billion to $1.09 Billion (18.52% CAGR). Check Amoy Diagnostics Co Ltd (300685) share price today for real-time trading data and today's change.
Amoy Diagnostics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amoy Diagnostics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300685 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.98x
Amoy Diagnostics Co Ltd's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.26x
Amoy Diagnostics Co Ltd's market cap is 3.26 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.03 Billion | $330.37 Million | $94.07 Million | 3.11x | 10.93x |
| 2018 | $837.16 Million | $439.03 Million | $126.74 Million | 1.91x | 6.61x |
| 2019 | $1.37 Billion | $578.36 Million | $135.47 Million | 2.37x | 10.13x |
| 2020 | $2.42 Billion | $728.39 Million | $180.33 Million | 3.32x | 13.42x |
| 2021 | $2.34 Billion | $917.03 Million | $239.57 Million | 2.55x | 9.78x |
| 2022 | $1.49 Billion | $842.18 Million | $263.74 Million | 1.77x | 5.65x |
| 2023 | $1.24 Billion | $1.04 Billion | $261.48 Million | 1.19x | 4.76x |
| 2024 | $1.30 Billion | $1.11 Billion | $254.86 Million | 1.17x | 5.11x |
| 2025 | $1.17 Billion | $1.20 Billion | $357.89 Million | 0.98x | 3.26x |
Competitor Companies of 300685 by Market Capitalization
Companies near Amoy Diagnostics Co Ltd in the global market cap rankings as of November 1, 2026. Also see 300685 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Amoy Diagnostics Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Amoy Diagnostics Co Ltd (2017–2026)
Market capitalization of Amoy Diagnostics Co Ltd from 2017 to today. Between 2017 and today, Amoy Diagnostics Co Ltd's market cap moved from $1.03 Billion to $ 1.09 Billion, with a yearly change of 18.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.09 Billion | -6.70% |
| 2025 | CN¥1.17 Billion | -10.26% |
| 2024 | CN¥1.30 Billion | +4.60% |
| 2023 | CN¥1.24 Billion | -16.46% |
| 2022 | CN¥1.49 Billion | -36.40% |
| 2021 | CN¥2.34 Billion | -3.23% |
| 2020 | CN¥2.42 Billion | +76.35% |
| 2019 | CN¥1.37 Billion | +63.92% |
| 2018 | CN¥837.16 Million | -18.60% |
| 2017 | CN¥1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Amoy Diagnostics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.09 Billion USD |
| MoneyControl | $1.09 Billion USD |
| MarketWatch | $1.09 Billion USD |
| marketcap.company | $1.09 Billion USD |
| Reuters | $1.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more